News

The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 and changes to and impact on the 2019 ABPI Code of Practice for the Pharmaceutical Industry

Press release: 16 February 2021

Updates to prescribing information for centrally approved medicines and other medicines from 1 January 2021

Press release: 16 February 2021

Vifor Pharma, Napp, Otsuka Europe, Otsuka UK , Teva UK, Bayer, Janssen, Merck Serono, Britannia, Novo Nordisk, Rayner and Shionogi Europe named in advertisements for breaches of the ABPI Code

Press release: 01 February 2021

Forthcoming 2021 ABPI Code

Press release: 15 January 2021

New Chair of the Code of Practice Appeal Board

Press release: 11 December 2020

Colonis Pharma has been named in advertisements for breaches of ABPI Code.

Press release: 25 September 2020

Merck Sharp & Dohme, Gilead Sciences Europe, Daiichi-Sankyo and Allergan have been named in advertisements for breaches of ABPI Code.

Press release: 25 September 2020

Pfizer and Bristol Myers Squibb, The Alliance, named in advertisements for breaches of the ABPI Code of Practice

Press release: 25 September 2020

PMCPA launches search for a new Chair of the Code of Practice Appeal Board

Press release: 05 August 2020

PMCPA issues additional draft working document to support the Consultation on the proposed 2021 ABPI Code of Practice for the Pharmaceutical Industry

Press release: 23 July 2020

Mr William Harbage QC, Chair of the Code of Practice Appeal Board

Press release: 14 July 2020

Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded

Press release: 25 June 2020

News

PMCPA News